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Abstract
GPR18, GPR55 and GPR119 (provisional nomenclature), although showing little structural similarity to CB1
and CB2 cannabinoid receptors, respond to endogenous agents analogous to the endogenous cannabinoid
ligands, as well as some natural/synthetic cannabinoid receptor ligands [98]. Although there are multiple reports
to indicate that GPR18, GPR55 and GPR119 can be activated in vitro by N-arachidonoylglycine,
lysophosphatidylinositol and N-oleoylethanolamide, respectively, there is a lack of evidence for activation by
these lipid messengers in vivo. As such, therefore, these receptors retain their orphan status.
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